Close Menu

NEW YORK (GenomeWeb) – Danaher has completed its roughly $13.8 billion acquisition of Pall, a provider of filtration, separation, and purification products for life sciences and other applications.

Under terms of the merger, each outstanding share of Pall common stock was cancelled and converted into the right to receive $127.20 per share in cash.

The firms inked the deal in May. The $13.8 billion price tag includes assumed debt and is net of acquired cash.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.